Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: An FDA pooled analysis

Lynn J. Howie, Harpreet Singh, Erik Bloomquist, Suparna Wedam, Laleh Amiri-Kordestani, Shenghui Tang, Rajeshwari Sridhara, Jacqueline Sanchez, Tatiana M. Prowell, Paul G. Kluetz, Belinda L. King-Kallimanis, Jennifer J. Gao, Amna Ibrahim, Kirsten B. Goldberg, Marc Theoret, Richard Pazdur, Julia A. Beaver

Research output: Contribution to journalArticle

Abstract

PURPOSE Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval of three agents in this class. The current pooled analysis examines the efficacy and safety of this combination in older women. PATIENTS AND METHODS We pooled data from three randomized controlled studies (N = 1,827) of different CDK4/6 inhibitors in combination with an AI for initial treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. The effect of age on progression-free survival was evaluated using Kaplan-Meier estimates and a Cox proportional hazards regression model. RESULTS For patients age 75 years or older (n = 198) who were treated with a CDK4/6 inhibitor and an AI, hazard ratio was 0.49 (95% CI, 0.31 to 0.76) with an estimated median progression-free survival of 31.1 months (95% CI, 20.2 months to not reached) versus 13.7 months (95% CI, 10.9 months to 24.9 months) for those treated with an AI. Incidence of grade 3 to 4 adverse events was 88.8% in patients age 75 years and older and 73.4% in patients younger than age 75 years. Patients age 75 years or older reported a decline in quality-of-life measures using the EQ-5D regardless of treatment with AI alone or with the addition of a CDK4/6 inhibitor. CONCLUSION There was similar efficacy with a CDK4/6 inhibitor in combination with an AI compared with AI alone for first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer in older women compared with younger patients. Patients older than age 75 years experienced higher rates of toxicity, dose modifications, and a decrease from baseline in quality-of-life measures.

Original languageEnglish (US)
Pages (from-to)3475-3483
Number of pages9
JournalJournal of Clinical Oncology
Volume37
Issue number36
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Howie, L. J., Singh, H., Bloomquist, E., Wedam, S., Amiri-Kordestani, L., Tang, S., Sridhara, R., Sanchez, J., Prowell, T. M., Kluetz, P. G., King-Kallimanis, B. L., Gao, J. J., Ibrahim, A., Goldberg, K. B., Theoret, M., Pazdur, R., & Beaver, J. A. (2019). Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: An FDA pooled analysis. Journal of Clinical Oncology, 37(36), 3475-3483. https://doi.org/10.1200/JCO.18.02217